AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer

Cambridge, MA -- 12/13/13
Back To Press & Events

CAMBRIDGE, MASS., December 13, 2013 – AVEO Oncology (NASDAQ: AVEO) today
announced that data from a planned interim analysis of the Phase 2 BATON
(Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer
(CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat
patient population.

BATON-CRC, led by Astellas, is an open-label, randomized Phase 2 study with a primary
endpoint evaluating the superiority of tivozanib in combination with modified FOLFOX6, a
standard chemotherapy, compared to bevacizumab in combination with modified FOLFOX6 as
first-line treatment in patients with advanced metastatic CRC. A component of the BATON-CRC study is the assessment of biomarker relationships that may be predictive of response in select, pre-defined patient subpopulations.

Data from the planned interim analysis, including biomarker data, are being analyzed, and
AVEO and Astellas are in discussions regarding next steps.

Share On Twitter Linkedin